Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Importance Pituitary adenomas are neoplasms of the pituitary adenohypophyseal cell
lineage and include functioning tumors, characterized by the secretion of pituitary hormones …

Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …

Objective Clinical paradigms and consensus recommend dopamine agonists (DAs) as the
primary treatment for prolactinomas. However, medically treated patients also encounter …

Prolactinomas are the commonest form of pituitary neuroendocrine tumor (PitNET),
representing approximately half of such tumors. Dopamine agonists (DAs) have traditionally …

Initial treatment for prolactinoma is usually conservative with dopamine agonists. However,
the duration of treatment is often lifelong and can be associated with significant side effects …

Objective First-line prolactin-secreting tumor (PST) management typically involves treatment
with dopamine agonists and the role of surgery remains to be further explored. We …

Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical
attention and are an important cause of hypogonadism and infertility. The ultimate goal of …

The current treatment paradigm for prolactinomas involves dopamine agonist (DA) therapy
as the first-line treatment, with surgical resection reserved for cases where there is DA failure …

Statement. Nat. Rev. Endocrinol. 19, 722–740 (2023) 1), which highlights rare but serious
dopamine agonist-related toxicities, such as impulse control disorders, as we demonstrated …